All In Biotech

Drug Trial Radar · NCT00844597

Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

Clinical Study to Assess the Safety fo AVI-4658 in Subjects With Duchenne Muscular Dystrophy Due to a Frame-shift Mutation Amenable to Correction by Skipping Exon 51.

Last checked: Nov 20, 2026Latest source record: Oct 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Jan 2009

Primary completion

Jun 2010

Study completion Dec 2010

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
British Medical Research Council
First posted
Feb 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 5 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • AVI-4658 for InjectionDrug

    AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Baseline to 6 months
  2. Treatment Emergent Adverse EventsTime frame: from Baseline to Follow up (27 weeks)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Great Ormond Street Hospital

    London, England, United Kingdom

  • Royal Victoria Infirmary

    Newcastle upon Tyne, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.